Investors Purchase Large Volume of GoodRx Call Options (NASDAQ:GDRX)

GoodRx Holdings, Inc. (NASDAQ:GDRX) saw some unusual options trading on Monday. Stock investors purchased 8,411 call options on the stock. This represents an increase of 1,884% compared to the typical daily volume of 424 call options.

GoodRx Stock Performance

GDRX traded down $0.05 on Monday, hitting $4.77. 295,807 shares of the stock traded hands, compared to its average volume of 1,064,454. The firm has a market capitalization of $1.82 billion, a PE ratio of -158.83, a P/E/G ratio of 2.46 and a beta of 1.28. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70. GoodRx has a 52 week low of $4.09 and a 52 week high of $9.26. The business has a fifty day moving average price of $4.67 and a two-hundred day moving average price of $5.80.

Analyst Ratings Changes

Several equities analysts have recently issued reports on GDRX shares. KeyCorp lowered their price target on GoodRx from $7.00 to $6.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th. Barclays reduced their price objective on GoodRx from $10.00 to $6.00 and set an “overweight” rating for the company in a research note on Monday, November 11th. Mizuho began coverage on GoodRx in a research note on Wednesday, December 4th. They set a “neutral” rating and a $5.00 price objective for the company. Citigroup decreased their target price on GoodRx from $7.00 to $6.25 and set a “buy” rating for the company in a research report on Friday, January 10th. Finally, Morgan Stanley decreased their target price on GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a research report on Tuesday, December 17th. Five research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, GoodRx has a consensus rating of “Moderate Buy” and a consensus target price of $8.38.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. National Bank of Canada FI boosted its holdings in shares of GoodRx by 34.9% in the 4th quarter. National Bank of Canada FI now owns 8,308 shares of the company’s stock worth $39,000 after acquiring an additional 2,151 shares in the last quarter. Gotham Asset Management LLC boosted its holdings in shares of GoodRx by 31.0% in the 4th quarter. Gotham Asset Management LLC now owns 17,677 shares of the company’s stock worth $82,000 after acquiring an additional 4,182 shares in the last quarter. Gagnon Securities LLC boosted its holdings in shares of GoodRx by 9.9% in the 4th quarter. Gagnon Securities LLC now owns 69,867 shares of the company’s stock worth $325,000 after acquiring an additional 6,266 shares in the last quarter. Swiss National Bank boosted its holdings in shares of GoodRx by 4.1% in the 4th quarter. Swiss National Bank now owns 161,400 shares of the company’s stock worth $751,000 after acquiring an additional 6,400 shares in the last quarter. Finally, Fortem Financial Group LLC raised its position in GoodRx by 7.2% in the 4th quarter. Fortem Financial Group LLC now owns 119,179 shares of the company’s stock worth $554,000 after purchasing an additional 7,996 shares during the last quarter. 63.77% of the stock is owned by institutional investors and hedge funds.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.